TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors.
about
Antiangiogenic gene therapy of cancer: recent developmentsInterventional Nanotheranostics of Pancreatic Ductal AdenocarcinomaTNFerade, an innovative cancer immunotherapeuticCurrent clinical trials testing the combination of immunotherapy with radiotherapy.Radiation-guided gene therapy of cancer.Therapy for unresectable recurrent and in-transit extremity melanoma.Alternate serotype adenovector provides long-term therapeutic gene expression in the eye.Suppression of cancer growth by nonviral gene therapy based on a novel reactive oxygen species-responsive promoter.A multipurpose microfluidic device designed to mimic microenvironment gradients and develop targeted cancer therapeutics.Electrochemotherapy as an adjunct or alternative to other treatments for unresectable or in-transit melanoma.Radiotherapy sensitization by tumor-specific TRAIL gene targeting improves survival of mice bearing human non-small cell lung cancer.Radiation improves gene delivery by a novel transferrin-lipoplex nanoparticle selectively in cancer cells.Combinations of immunotherapy and radiation in cancer therapy.Tumor-specific apoptotic gene targeting overcomes radiation resistance in esophageal adenocarcinomaLiposome encapsulated zoledronate favours M1-like behaviour in murine macrophages cultured with soluble factors from breast cancer cells.Gene therapy for cancer treatment: past, present and futureEUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatment of locally advanced pancreatic cancer: a phase I/II study.The development of a novel cancer immunotherapeutic platform using tumor-targeting mesenchymal stem cells and a protein vaccineEmerging drugs for head and neck cancer.Direct therapeutic intervention for advanced pancreatic cancer.The use of gene therapy in cancer research and treatment.Gene therapy strategies to improve the effectiveness of cancer radiotherapy.Regulatable gene expression systems for gene therapy applications: progress and future challenges.Radiogenic therapy: novel approaches for enhancing tumor radiosensitivity.Ionizing radiation: a genetic switch for cancer therapy.Combining radiotherapy and immunotherapy: a revived partnership.New concepts for phase I trials: evaluating new drugs combined with radiation therapy.Gene delivery and gene therapy of prostate cancer.Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitisRecent clinical progress in virus-based therapies for cancer.Endoscopic ultrasound-guided oncologic therapy for pancreatic cancer.Randomized phase III multi-institutional study of TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: final resultsA phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation.Turning the gene tap off; implications of regulating gene expression for cancer therapeutics.Immunotherapy and immunoescape in colorectal cancer.Endoscopic ultrasound-guided intratumoural therapy for pancreatic cancer.Targeted Cancer Therapy with Tumor Necrosis Factor-Alpha.Borderline resectable pancreatic cancer: on the edge of survival.Hypoxia- and radiation-induced overexpression of Smac by an adenoviral vector and its effects on cell cycle and apoptosis in MDA-MB-231 human breast cancer cells.Future of targeted agents in metastatic colorectal cancer.
P2860
Q24803786-456169E1-4D02-4BEA-930D-09D2F0B2C705Q26744830-EF609864-76C2-4B7D-A694-A8C24DD3F607Q26776326-7288DE46-9B6A-4016-9BFD-8C773ED4720CQ30356447-10A69808-D278-4906-9B03-DC216970600CQ33251692-013B747B-5224-4A4B-88F5-A0BB350B99A9Q33348506-C025B830-2EEB-40DE-BBE0-21766B15AE8BQ33397385-B9BFC561-6273-4201-A030-8BDABDA166A1Q33713915-5608472E-E263-42C9-B533-1E50F9043CD1Q33792264-04FAD787-A9A5-4406-8889-60042014B0D4Q34020065-1534B83F-2E21-4199-B31E-E8DE11469E04Q34313135-B2412AE1-4832-4A23-87F9-4599C55125D5Q34387454-373AF48D-D754-411C-981F-D36317343565Q34582640-2DC26A21-A96C-46A4-BA7A-99CE897A003AQ34595455-8720B7D6-7384-4B84-8357-E41DE62E3FA9Q35008733-A8A2B452-9D8C-4667-956F-3F83BAEC150DQ35040146-E719A6B7-CCCD-458E-AA0C-EAC0B5233906Q35234491-CF36573F-8414-4CA3-9AF6-E2E4E6208136Q35623444-0A97AC11-D457-4D72-B3CA-02FC0B73AE55Q35779289-0FBCDE09-B07C-4F33-AA4D-19C7B62A6C39Q35871364-B813AADC-BA5F-4B39-B68A-33FB656319C7Q35904008-1920E30E-FC06-4B39-BAA6-1AC6275B1008Q35925611-9FF40C4F-2754-4DFE-A78F-58ABD508615DQ36157542-0E05FA0E-755D-48AD-8C67-DD985FFB9B6FQ36200146-4B3732AB-01AE-4873-8C95-CE310B6E4519Q36219322-FCD69A2E-AD85-483C-A066-10B775F5EC9BQ36274581-B1F42C7B-68E7-455E-8998-A066693CE530Q36304022-18AA1D7B-83EE-4874-B6DA-12DE9DC0D682Q36349678-89220068-5C62-4B59-A2E9-84EB886A7287Q36404110-571C534B-C6CF-4C8B-8338-BA71C5CCAB0FQ36627242-56C1E796-6B5E-475A-8CCA-77D8F1E301C3Q36679117-231C9DE5-F04A-4F07-A873-7461F1738277Q36764997-B4209431-16C6-4812-AB4B-9672D0A90FABQ36870401-4C681A94-8403-4952-8EBC-A3B698EF32FCQ36994041-9A6B6526-0FE9-40C2-BA3F-2A6948FBC67FQ36996316-EC444F8F-2BD4-419B-8D12-5857236D31CEQ37139338-67893702-B201-44F1-9AB2-F542E34B27EBQ37220415-F2C6DA21-BCBB-4B16-B431-480CF4F8DC05Q37277969-089ED8D1-3EB3-4991-A19E-E86592A58B95Q37313184-347F268F-7DEA-48DE-AB64-852A20B97517Q37326863-4BE1C3D8-623A-43E4-935C-8342CBC09FED
P2860
TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
TNFerade biologic, an adenovec ...... in patients with solid tumors.
@en
type
label
TNFerade biologic, an adenovec ...... in patients with solid tumors.
@en
prefLabel
TNFerade biologic, an adenovec ...... in patients with solid tumors.
@en
P2093
P356
P1476
TNFerade biologic, an adenovec ...... in patients with solid tumors.
@en
P2093
Alexander Rosemurgy
Camilla Rasmussen
Casey Cunningham
Chandan Guha
Donald Kufe
Henrik Rasmussen
John Nemunaitis
Michelle Gillen
Nader Hanna
P304
P356
10.1200/JCO.2004.01.227
P407
P577
2004-01-15T00:00:00Z